.png){kind=icon}
.png){kind=icon}
Return
A randomized, open-label, phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis
.png){kind=icon}
PRE
AI
C
E
R
W
L
S
K
O
H
J
DOI：10.1097/HEP.0000000000001748.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background and Aims: Ammonia is central in the pathogenesis of HE, but there are no approved treatments targeting ammonia. L-Ornithine Phenylacetate (YAQ007) is a novel drug that effectively reduces ammonia when administered intravenously. This exploratory phase 2a study evaluated the short-term pharmacodynamics, pharmacokinetics, and safety of oral YAQ007 in patients with cirrhosis and a history of overt HE. Approach and Results: In this randomized, open-label, multicenter study, 48 cirrhosis patients (28 male, mean of 57.2 y, Child-Pugh of 8, and MELD score of 10) were randomized (1:1:1:1) to 1 of 3 YAQ007 dosing regimens (2 g three times daily; 4 g twice daily; 4 g three times daily) or rifaximin (550 mg twice daily) for 5 days under inpatient conditions. A decrease of ammonia at day 5 was observed in group C (p=0.009) and group B (p=0.002). After multivariable adjustment, treatment group B versus group D, bilirubin, INR, and sodium (p<0.05) remained significant factors for absolute ammonia reduction. Urinary phenylacetylglutamine excretion increased on day 5 compared with day 1 across all YAQ007 dose groups (p<0.001). Exposure-response relationships were variable, and a clear dose-response relationship was not demonstrated. Overall, 20 (55.6%) patients who received YAQ007 and 5 (41.7%) who received rifaximin had at least 1 treatment-emergent adverse event, with mainly mild gastrointestinal and neurological symptoms. Conclusions: In this phase 2a study, oral YAQ007 demonstrated short-term ammonia-lowering activity at doses >= 4 g BID. Given the exploratory design, these findings are hypothesis-generating and support further clinical evaluation.
Keywords:
ammonia
cirrhosis
HE
ornithine phenylacetate
rifaximin
Journal
IF:
15.8
Papers:
2.0W
Citations:
7.2W
Organization
Cited Papers